| Title |
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
|
|---|---|
| Published in |
Vascular Health and Risk Management, May 2012
|
| DOI | 10.2147/vhrm.s31758 |
| Pubmed ID | |
| Authors |
Sylvie Dejager, Anja Schweizer, James E Foley |
| Abstract |
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years' duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin in monotherapy. Consideration based on baseline glycated hemoglobin levels and age is given to patient segments where metformin is not appropriate. In addition, although prediabetes is not an indication, this manuscript briefly reviews some of the existing data showing that the mechanisms at work in diabetic populations are active in patients currently classified as prediabetic, with impaired glucose tolerance or impaired fasting glucose. Finally, the rationale for vildagliptin dosing frequency in monotherapy is discussed. In summary, this review aims to define where in community practice the use of vildagliptin as monotherapy is most desirable, focusing on segments of the population with type 2 diabetes mellitus that might receive the greatest benefit from vildagliptin in the management of their disease. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 2% |
| India | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 56 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 20% |
| Student > Master | 11 | 19% |
| Other | 6 | 10% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Postgraduate | 5 | 8% |
| Other | 11 | 19% |
| Unknown | 8 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 12% |
| Agricultural and Biological Sciences | 5 | 8% |
| Nursing and Health Professions | 2 | 3% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 11 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 May 2012.
All research outputs
#17,438,425
of 25,584,565 outputs
Outputs from Vascular Health and Risk Management
#531
of 785 outputs
Outputs of similar age
#115,719
of 176,069 outputs
Outputs of similar age from Vascular Health and Risk Management
#9
of 14 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 785 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,069 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.